ABSTRACT Introduction Neutralizing antibodies (NAbs) that target key domains of the spike
protein in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may have …

Background We aimed to quantitatively summarise the health economic evaluation
evidence of prevention and control programs addressing COVID-19 globally. Methods We …

Background Real-world data is currently limited on the association between oral antiviral
therapy and healthcare system burden in patients with mild-to-moderate COVID-19. This …

Objectives The COVID-19 pandemic has had a major impact on our society, with drastic
policy restrictions being implemented to contain the spread of the severe acute respiratory …

Objectives As healthcare systems continue to respond to the COVID-19 pandemic, cost-
effectiveness evidence will be needed to identify which tests and treatments for COVID-19 …

Background The COVID-19 outbreak was defined as a pandemic on 11 March 2020 by the
World Health Organization. After that, COVID-19 has enormously influenced health systems …

Background This article investigates the hospital costs related to the management of COVID-
19 positive patients, requiring a hospitalization (from the positivity confirmation to discharge …

A pandemic poses particular challenges to decision-making because of the need to
continuously adapt decisions to rapidly changing evidence and available data. For example …

Abstract Background Regdanvimab (CT-P59) is a neutralizing antibody authorized in
Republic of Korea for the treatment of adult patients with moderate or mild-COVID-19 who …

This paper studies a dynamic vaccination game model embedded with vaccine cost-
effectiveness and dyadic game during an epidemic, assuming the appearance of …